Senses Disorder TRIZ Cases

Small-molecule glucagon receptor antagonists lower blood glucose by blocking hepatic glucose production, avoiding hypoglycemia and insulin resistance.

A targeted cytotoxic composition eliminates skeletal muscle stem cells to prevent lens fibrotic diseases.

Ophthalmic formulation containing telomerase activators boosts corneal cell viability through targeted biochemical stimulation.

Formula I compounds selectively block JAK1 and TYK2 to treat inflammatory disorders while reducing toxicity from broad immunosuppression.

A choline compound, cholinesterase inhibitor, and Acetyl-L-Carnitine composition stimulates post-ganglionic nicotinic receptors to restore tear production.

Sulphonamide compounds inhibit NLRP1 and NLRP3 inflammasomes, reducing IL-1β production to treat autoimmune disorders.

Modulating NR1H4 receptors with specific agonists improves bile acid metabolism while reducing gallstone formation risks.

Modified botulinum transport protein binds nerve cells via enhanced ganglioside affinity, extending treatment intervals and reducing antibody formation.

Segmented HIF-1α inhibitors reduce pathological blood vessel growth in diabetic retinopathy.

Novel heterocyclic carboxamides inhibit p70S6K and AKT pathways, resolving bioavailability trade-offs for cancer treatment.

Cellulose hydrogel membranes provide high tensile strength and transparency for wound dressings.

Specific 5H-pyrido[4,3-b]indole compounds inhibit JAK kinases and PDK1 to treat myeloproliferative disorders lacking effective therapeutic options.

Liposomal miotic composition applied to eyelids improves visual acuity without inducing miosis or myopia.

Specific amino acid substitutions in a TNFRI polypeptide increase protease resistance, resolving degradation issues that limit half-life and bioavailability.

A dual-target antibody binds VEGFR-2 and DLL4 to inhibit angiogenesis.

Glutathione diethyl ester thioethylguanidine disulfide blocks oxidative stress to prevent advanced glycation end product accumulation.

Sulfonamido derivatives replace hydroxamate groups to reduce P450 enzyme affinity while maintaining potent histone deacetylase inhibition.

Combining a PCSK9 inhibitor antibody with maximum tolerated dose statin therapy lowers LDL-C by 60% or more, resolving inadequate lipid control.

A low viscosity peptide pre-formulation undergoes phase transition upon contact with aqueous fluids to form a controlled release composition.

Dobesilate normalizes retinal architecture and improves visual acuity through intravitreal administration.

Oxygen treatment during tribo-mechanical micronization modifies zeolite surface chemistry to increase specific surface area.

iMIT method isolates mitochondria using sub-critical surfactant concentrations to preserve membrane integrity and functional capability.

Pyrrole compounds inhibit S-nitrosoglutathione reductase, maintaining elevated nitric oxide levels to treat disorders linked to imbalance.

A unit dose combining thiamine, pyridoxine, quercetin, and curcumin inhibits advanced glycation end product formation.

Developing specific heterocyclic structures overcomes the lack of targeted modulators, improving therapeutic effectiveness for neurological conditions.

Antibodies target unique MMP9 catalytic domain epitopes to inhibit the enzyme without affecting homologous MMP2, resolving selectivity challenges.

Nitrogenous tricyclic compounds bind to the FXR nuclear receptor to regulate metabolic activity.

Fusion proteins combine PDGF and VEGF binding domains to inhibit both pathways, reducing neovascularization resistance in ocular diseases.

Topical phentolamine reduces intraocular pressure while minimizing eye redness and adverse events.

Aromatic-cationic peptides target SURF1 or POLG mutations to correct biochemical defects, reducing symptom severity and improving cellular function.

Replacing a polar hydroxyl group with a benzene ring enables 4-PSB-2 to cross the cell membrane and inhibit inflammatory responses in optic nerve crush injury.

Anti-IL-1β antibodies neutralize IL-1β to treat refractory uveitis, reducing inflammation and vision loss risks.

Chimeric aptamers merge PDGF-B and VEGF binding to block angiogenesis without complex regimens.

Epitope peptides induce cytotoxic T cells targeting VEGFR1-expressing endothelial cells, suppressing tumor growth without frequent high-dose administration.

Engineered manganese superoxide dismutase variants selectively penetrate cancer cells to induce apoptosis while sparing normal cells from oxidative damage.

High concentration vitamin B complex formulations slow age-related macular degeneration progression by stabilizing retinal cellular metabolism.

Benzyl-substituted quinolone compounds modulate muscarinic M1 receptors via allosteric sites, addressing underlying pathology while avoiding side effects.

A composite solvent system of benzyl benzoate and polyethylene glycol forms stable spherical depots, resolving shape instability across administration sites.

Biaryl derivative GPR120 agonists resolve limited disease coverage by promoting GLP-1 generation and enhancing anti-inflammatory actions.

A stable Form I solid dosage of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid modulates CFTR activity.

Prodrug formulations resolve storage stability versus patient compliance contradictions by enabling ready-to-use solutions for glaucoma treatment.

XTEN polypeptides replace PEG to extend half-life while avoiding metabolite accumulation and antibody induction.

Recombinant human nerve growth factor targets peripheral neuropathic corneal pain mechanisms, avoiding ineffective broad application to non-responsive subtypes.

Introducing PEST motifs into the neurotoxin light chain reduces muscle paralysis duration while maintaining therapeutic efficacy.

Spiro-substituted compounds inhibit protein tyrosine kinases via irreversible binding, reducing tumor growth and vascular permeability in angiogenic diseases.

Culturing pluripotent stem cells with sequential FGF, MEK, Rho, and apoptosis inhibitors to generate retinal pigment epithelial cells.